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Proteomic Profiling of Cranial (Superior)
Cervical Ganglia Reveals Beta-Amyloid and
Ubiquitin Proteasome System Perturbations in
an Equine Multiple System Neuropathy*□S
Bruce C. McGorum‡**, R. Scott Pirie‡, Samantha L. Eaton§, John A. Keen‡,
Elizabeth M. Cumyn§, Danielle M. Arnott§, Wenzhang Chen¶, Douglas J. Lamont¶,
Laura C. Graham§, Maica Llavero Hurtado§, Alan Pemberton‡, and
Thomas M. Wishart§**
Equine grass sickness (EGS) is an acute, predominantly
fatal, multiple system neuropathy of grazing horses with
reported incidence rates of 2%. An apparently identical
disease occurs in multiple species, including but not lim-
ited to cats, dogs, and rabbits. Although the precise eti-
ology remains unclear, ultrastructural findings have sug-
gested that the primary lesion lies in the glycoprotein
biosynthetic pathway of specific neuronal populations.
The goal of this study was therefore to identify the mo-
lecular processes underpinning neurodegeneration in
EGS. Here, we use a bottom-up approach beginning with
the application of modern proteomic tools to the analysis
of cranial (superior) cervical ganglion (CCG, a consistently
affected tissue) from EGS-affected patients and appropri-
ate control cases postmortem. In what appears to be the
proteomic application of modern proteomic tools to
equine neuronal tissues and/or to an inherent neurode-
generative disease of large animals (not a model of human
disease), we identified 2,311 proteins in CCG extracts,
with 320 proteins increased and 186 decreased by greater
than 20% relative to controls. Further examination of se-
lected proteomic candidates by quantitative fluorescent
Western blotting (QFWB) and subcellular expression pro-
filing by immunohistochemistry highlighted a previously
unreported dysregulation in proteins commonly associ-
ated with protein misfolding/aggregation responses seen
in a myriad of human neurodegenerative conditions, in-
cluding but not limited to amyloid precursor protein (APP),
microtubule associated protein (Tau), and multiple com-
ponents of the ubiquitin proteasome system (UPS). Differ-
entially expressed proteins eligible for in silico pathway
analysis clustered predominantly into the following bio-
functions: (1) diseases and disorders, including; neurolog-
ical disease and skeletal and muscular disorders and (2)
molecular and cellular functions, including cellular as-
sembly and organization, cell-to-cell signaling and inter-
action (including epinephrine, dopamine, and adrenergic
signaling and receptor function), and small molecule bio-
chemistry. Interestingly, while the biofunctions identified
in this study may represent pathways underpinning EGS-
induced neurodegeneration, this is also the first demon-
stration of potential molecular conservation (including
previously unreported dysregulation of the UPS and APP)
spanning the degenerative cascades from an apparently
unrelated condition of large animals, to small animal mod-
els with altered neuronal vulnerability, and human neuro-
logical conditions. Importantly, this study highlights the
feasibility and benefits of applying modern proteomic
techniques to veterinary investigations of neurodegenera-
tive processes in diseases of large animals. Molecular &
Cellular Proteomics 14: 10.1074/mcp.M115.054635, 3072–
3086, 2015.
Equine grass sickness (EGS, or equine dysautonomia) is a
predominantly fatal, rapid multiple system neuropathy of
grazing horses with reported incidence rates of 2.1–2.3%
(reviewed by (1, 2)). An apparently identical disease occurs in
cats, dogs, hares, rabbits, llamas, and possibly sheep (3–9).
EGS is associated with chromatolysis of sympathetic and
parasympathetic postsynaptic neurons, particularly in the en-
teric nervous system, as well as autonomic presynaptic and
somatic lower motor neurons in the brainstem and spinal cord
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(10). EGS is subdivided into acute, subacute, and chronic
forms according to the severity of clinical signs that largely
reflect enteric and autonomic neurodegeneration, including
dysphagia, generalized ileus, sweating, salivation, ptosis,
rhinitis sicca, and tachycardia. While the etiology of EGS
remains unknown, some evidence supports it being a toxic
infection with Clostridium botulinum type C or D (11, 12).
Ultrastructural studies suggest that the lesion in EGS pri-
marily involves the glycoprotein biosynthetic pathway of
specific neurons since the rough endoplasmic reticulum and
Golgi complexes are consistently affected, while other or-
ganelles, including mitochondria, appear relatively normal
(13). However, while the ultrastructural and cellular appear-
ance of affected neurons has been studied extensively, little
is known about the molecular mechanisms that contribute
to neurodegeneration.
The overarching aim of this study was therefore to identify
the molecular processes underpinning neurodegeneration in
EGS using a bottom-up approach beginning with the appli-
cation of modern proteomic tools to the analysis of cranial
(superior) cervical ganglion (CCG, a consistently affected tis-
sue) from EGS-affected patients and appropriate control
cases postmortem. The cranial (superior) cervical ganglion
(CCG), which supplies sympathetic innervation to the head
and neck, was selected because chromatolysis of a high
proportion of CCG neurons is a consistent feature of EGS (Fig.
1 and Supplemental Fig. 1 (14)). Here, proteomic analysis was
carried out using isobaric tag for relative and absolute quan-
titation (iTRAQ) tools, which are now well established in small
animal models of human neurodegenerative conditions but
which are not routinely utilized in large animal models or large
animal intrinsic conditions. This proteomic analysis was cou-
pled with quantitative fluorescent Western blotting (QFWB),
immunohistochemistry (IHC), and in silico based techniques in
an attempt to identify the molecular pathways and processes
that may be contributing to neurodegeneration in EGS. Here,
we report widespread changes in the CCG of EGS horses,
including significant disruption to a broad range of functional
pathways clustering around candidates commonly associ-
ated with protein misfolding/aggregation responses in human
neurodegenerative conditions.
This study therefore represents the first application of mod-
ern proteomic tools to equine neuronal tissues and/or to an
inherent neurodegenerative disease of large animals (not a
model of human disease). It is also the first to demonstrate
correlation and conservation spanning the degenerative mo-
lecular cascades from an apparently unrelated condition of
large animals to small animal models with altered neuronal
vulnerability and a range of human neurological conditions
from childhood neurodegenerative conditions such as spinal
muscular atrophy through to diseases associated with ad-
vancing age such as Alzheimer’s. Finally, this study highlights
the feasibility and benefits of applying differential proteomics
techniques to the investigation of the neurodegenerative pro-
cesses in diseases of large animals.
MATERIALS AND METHODS
In accordance with MCP guidelines, more detailed discussion of
experimental design and potential limitations can be found in the
accompanying Supplementary Discussion file. General methodology
is provided below.
Ethics Statement—Tissue samples were collected at necropsy
from horses that were euthanized on humane grounds, with the horse
owners’ consent. The study was approved by the local ethics
committee.
Collection of Ganglia—For proteomics and quantitative fluorescent
Western blotting, CCG were collected from six EGS (median age 6
years, range 3–17) and six control (14, 6–30 years) mixed-breed and
mixed-gender horses within 60 min of euthanasia by administration of
barbiturates (Table I). CCG were selected because chromatolysis of a
high proportion of CCG neurons is a consistent feature of EGS (see
Fig. 1) (14). The heterogeneity in breed, sex, and age of EGS horses
used in the study reflects the spectrum of horses affected by this
spontaneous neurodegenerative disease during the study period.
EGS horses comprised three acute and three subacute cases, as
categorized by McGorum and Kirk (15). The grouping of acute and
subacute cases for proteomic analysis was carried out as there are
only minor differences in clinical features and pathology of these
phenotypes. The main difference is the length of disease process
following diagnosis. All of the samples are from post mortem terminal
patients and the anatomical and cellular hallmarks are consistent at
end stage regardless of case type. Moreover, we can demonstrate
that neuronal density does not differ between acute and subacute
cases (Supplemental Fig. 1). Due to these considerations and the fact
that the initiating insult remains unproven, molecular analyses are
currently performed on pooled samples as an attempt to reduce
“noise” due to interanimal variability through factors such as individ-
ual disease response, age, and breed, among other considerations.
EGS was confirmed in all cases by necropsy, including histopatho-
logical examination of autonomic ganglia (16). Controls were eutha-
nized on humane grounds for reasons other than neurological dis-
ease. Immediately after collection, CCG were rapidly frozen by
immersion in dry ice pellets and stored at 80 °C. For immunohisto-
chemistry, CCG were collected from six EGS (median age 8 years,
range 2–20) and six control (median age 11, 6–15 years) mixed-breed
and mixed-gender horses as described above (Table I) and fixed in
10% neutral buffered formalin and embedded in paraffin wax.
Protein Extraction—Ganglia were partially thawed, the outer fascia
removed by dissection, and a portion macerated with a scalpel before
partial homogenization in either radioimmune precipitation assay
buffer with protease inhibitor mixture (Roche) for QFWB (see below) or
iTRAQ extraction buffer containing 6 M Urea, 2 M thiourea, 2%
CHAPS, 0.5% SDS, and protease inhibitor mixture (Roche) for pro-
teomic processing (see below). Samples were pooled by condition
and manually homogenized in a dounce glass homogenizer. Homog-
enized samples were sonicated in a cup style sonicator six times for
15 s at power level 7.5 with vortexing for 30 s between each round of
sonication. Samples were left on ice for 10 min before being revor-
texed then centrifuged at 20,000 g for 30 min at 4 °C. The resulting
pellet containing proteins insoluble when processed in this manner
was stored at 80 °C, and the supernatant was transferred to a fresh
1.5 ml tube to be processed for iTRAQ labeling as previously de-
scribed (17–20).
iTRAQ Proteomic Analysis—Protein was extracted in iTRAQ ex-
traction buffer (6 M Urea, 2 M thiourea, 2% CHAPS, 0.5% SDS, and
protease inhibitor mixture (Roche, Burgess Hill, UK), (pH 7.4)) before
acetone precipitation and labeling for iTRAQ analysis. The Mass
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spectrometry proteomic data have been deposited to the ProteomeX-
change consortium via the PRIDE partner repository with the dataset
identifier PXD002956.
Protein extracts (n  6 ganglia per group; see Fig. 2) were precip-
itated with 20 °C chilled acetone (1:4, v/v) and stored at 20 °C
overnight. The precipitates were spun at 4 °C for 10 min then
washed with an acetone:water mixture (4:1, v/v) twice prior to air
drying. The pellets were then resuspended in iTRAQ sample buffer
(25 l 500 mM tetraethylammonium bromide, 1 l denaturant (2%
SDS), and 2 l of reducing agent Tris(2-carboxyethyl)phophine
(TCEP)). The samples were allowed to incubate for 1 h at 60 °C prior
to protein estimation in triplicate (3  1 l) by microBCA assay
(Pierce, Paisley, UK). Samples were run in duplicate to utilize all four
tags from the 4plex kit and increase peptide identification yield as
previously described (17–20).
Each sample equivalent to 100ug was processed separately using
the filter aided sample preparation (FASP) method prior to digestion
with trypsin (sequencing grade, Roche). After digestion, the samples
were dried using a SpeedVac concentrator and then resuspended in
25 l of dissolution buffer as provided in the iTRAQ Reagents Multi-
plex kit (AB Sciex, Warrington, UK). The samples were then labeled,
respectively, according to the protocol provided by the manufacturer
(AB Sciex). The four labeled samples (Control-115 and 117, EGS-114
and 116) were then pooled together in equal proportions and subse-
quently dried using a SpeedVac concentrator. The pooled iTRAQ
4plex sample was then desalted using a homemade porous R2 ZipTip
column and then fractionated by Strong Cation eXchange (SCX) using
a Polysulfoethyl A column (2.1  200 mm, 5 m, PolyLC) on a
Ultimate U3000 (Dionex, Loughborough, UK) hplc system. The fol-
lowing buffer system was used Buffer A: 5 mM KH2PO4 in 20%
CH3CN (pH 2.7) and buffer B: 500 mM NaCl in 5 mM KH2PO4 in 20%
CH3CN (pH 2.7).The flow rate was set to 0.2 ml per minute with a
linear gradient from 0 to 50% B over 25 min then a linear gradient
from 50 to 100% B over 9 min.
Each fraction from the SCX fractionation was then dried using a
SpeedVac concentrator and stored at 80 °C. Stored SCX fractions
of the pooled iTRAQ 4plex sample were then resuspended in 10 l of
5% formic acid, diluted to 1% formic acid, and then 15 l aliquots
injected onto an Ultimate RSLC nano UHPLC system coupled to a
LTQ Orbitrap Velos Pro (Thermo Scientific, Loughborough, UK). The
iTRAQ-labeled peptides were injected onto a trapping column (Ac-
claim PepMap 100, 100 m  2 cm, C18, 5 m, nanoViper) and then
FIG. 1. Equine grass sickness is a predominantly fatal, acute
multiple system neuropathy of grazing horses. (A) Example pho-
tograph of a horse exhibiting typical appearance associated with
chronic EGS. There is ptosis, and generalized muscle weakness as
evidenced by the base narrow stance, low head and neck carriage,
and leaning against a wall for support. Generalized muscle atrophy
and reduced abdominal volume are also evident. (B) Example BIII-
tubulin-stained sections from cranial cervical ganglia (CCG), which
are known to exhibit neuronal perturbations in this disease. The
visible puncta are BIII positive neurons. (C) High power micrographs
stained CCG sections from B showing BIII positive neuronal profiles.
(D) Quantification of BIII positive neurons demonstrates that there is
still equivalent neuronal density in ganglia at terminal stages of the
disease (control 6.25  0.12, EGS 6.10  0.20 cells per 100 m2,
mean Standard Error (S.E) n 4 cases per condition, n 116 grids
measured. See Materials and Methods for more information). (E)
Example H and E stained sections from control and EGS-affected
CCG demonstrates that while the neuronal density may be similar,
many of the neurons exhibit chromatolysis. Scale bar  0.75ft (A), 0.5
cm (B), 35 m (C), 100 m (E).
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separated using a 2 h linear gradient from 2–40% B (80% acetonitrile,
0.1% formic acid) on a separation column (Acclaim PepMap RSLC,
75 m  15 cm, C18, 2 m, nanoViper) at a flow rate of 300 nl/min.
The mass spectrometry parameters were set as follows: Fourier
transform mass spectrometry (FT-MS) (survey scan) resolution was
set at 60,000; the 15 most-intense precursor ions were chosen for
fragmentation by high energy collisional-induced dissociation (HCD);
the precursor isolation window was set at 1.2 Da; and the ms/ms scan
resolution was set to 7,500. Automatic gain control (AGC) values for
FT-MS and FT-MS/MS were set at 1e6 and 5e4 ions, respectively.
TABLE I
Subject information
FIG. 2. Schematic of iTRAQ workflow. Protein was extracted from six individual EGS and control horse CCG. Following separate
extractions, small amounts of each were pooled by condition. Pooled samples were then labeled and run in duplicate to use all of the tags from
an ITRAQ 4plex kit as previously described (17, 18, 19, 25). See Materials and Methods for further detail.
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The maximum fill times for FT-MS and FT-MS/MS were set at 500 and
200 ms, respectively.
The raw data were extracted using Proteome Discoverer (Version
1.4.1, Thermo Scientific) for both quantitation and for identification
by searching against the NCBI mammalia (database: NCBInr
20,121,028–21,171,493 sequences; 7,255,144,311 residues; taxon-
omy: mammalia (mammals) 1,173,629 sequences) and NCBI
bacteria (database: NCBInr 20,130,811–31,351,517 sequences;
10,835,265,410 residues; taxonomy: bacteria (eubacteria) 20,989,102
sequences) databases using the Mascot Search Engine (Version
2.4.1, Matrix Science, London, UK). Search parameters included the
following: enzyme: trypsin/P; fixed modifications (carbamidomethyl
(C)), iTRAQ4plex (N-term); variable modifications: oxidation (M), di-
oxidation (M), acetyl (N-term), Gln-pyro-Glu (N-term Q), iTRAQ4plex
(K), iTRAQ4plex (Y); peptide mass tolerance  10 ppm; fragment
mass tolerance  0.06 Da; maximum of two miss-cleavages. Thresh-
old score/expectation value for accepting individual spectra was
based on Mascot ion score threshold (0.05) as the standard ion score
threshold specifically calculated by Mascot for each database search.
As an indication of identification certainty, the false discovery rate for
peptide and protein matches above identity threshold were calculated
by Peptide Validator at 1.0% (strict) and 5.0% (relaxed), respectively.
Validation of Candidate Proteins—Validation of altered expression
levels for selected candidate proteins was carried out by quantitative
fluorescent Western blotting using CCG protein extracts and by im-
munohistochemistry on CCG sections. See Table II for a list of anti-
bodies and their compatibility with equine neural tissues.
Quantitative Fluorescent Western Blotting (QFWB)—QFWB was
carried out as previously described (21, 22). Briefly, 15 g of CCG
protein were separated by SDS-polyacrylamide gel electrophoresis
on 4–12% precast NuPage BisTris gradient gels (Invitrogen, Paisley,
UK) and then transferred to PVDF membrane using an iBLOT fast
transfer device (Invitrogen). The membranes were then blocked using
Odyssey blocking buffer (LICOR Biosciences, Cambridge, MA) and
incubated with primary antibodies according to manufacturers’ in-
structions (see Table II). Odyssey secondary antibodies were added
according to manufacturers’ instructions (goat anti-rabbit IRDye 680
and goat anti-mouse IRDye 800). Blots were imaged using an Odys-
sey Infrared Imaging System (LI-COR Biosciences). Scan resolution
of the instrument ranges from 21 to 339 m, and blots were imaged
at 169 m. Quantification was performed on single channels with the
analysis software provided. Total protein stain gels, loaded in parallel
with those used for membrane transfer, were used to ensure equiv-
ocal sample loading and were analyzed using the Odyssey Infrared
Imaging System as previously described in (21, 22).
Immunohistochemistry (IHC)—Formalin-fixed, paraffin-wax-em-
bedded CCGs were dewaxed and rehydrated. Antigen retrieval was
performed by heating sections in 0.1 M citrate buffer (pH 6.0) for 15
min in a pressure cooker. The slides were then left to cool for 20 min.
A commercial immunolabeling kit (DakoCytomation EnVision Sys-
tem-HRP; DAB K4001; DAKO, Ely, UK) was used according to the
manufacturer’s instructions. Slides were rinsed with Tris buffered
saline containing 0.5% Tween (pH 7.5; TBST) and incubated with
peroxidase blocking agent (Dako Real Peroxidase Blocker S2023) for
10 min. Slides were rinsed in TBST and incubated with murine mono-
clonal anti-human synaptophysin (Dako M0776) diluted 1 in 20 in
TBST for 60 min at 25 °C. TBST replaced primary antibody for neg-
ative controls. Slides were rinsed and incubated with horseradish
peroxidase-labeled polymer for 30 min then rinsed and incubated
with substrate chromogen solution (Liquid DAB; ImmPact Dab
SK4105; Vector Laboratories, Peterborough, UK) for 10 min. Slides
were rinsed once in distilled water, counterstained with Harris’s he-
matoxylin (1 min), dipped in Scott’s tap water substitute, dehydrated,
cleared using ethanol then xylene, and mounted under DPX. The
intensity of labeling of CCG neurons was assessed blindly. IHC for
B-APP, total Tau, and ubiquitin was carried out with antibodies de-
tailed in Table II, for 2 h at room temperature, following microwave
pretreatment in citrate buffer (pH 6), then labeled using the EnVision
tracer system. For neuronal cell number assessment BIII-tubulin (Ta-
ble II) IHC was carried out as described above and Neurotrace (Life-
Technologies, Paisley, UK, Table II) was employed following manufa-
cturer’s instructions. Sections were visualized using a Nikon Eclipse
E800 microscope, and whole sections were montaged by aligning
approximately 80 10X images per ganglia section using Adobe Pho-
toshop CS5.1 (V12.4) with the integrated Bridge module. BIII-tubulin
and neurotrace-based neuronal counts were carried out in image j by
overlaying a 10  10 square grid with each individual square meas-
uring 100 m2 (see Supplemental Fig. 1).
In Silico Protein Network Analysis—To obtain further insight into
potential cellular pathways that may be modified as a result of protein
changes identified in our experiments, the Ingenuity Pathways Anal-
ysis (IPA) application (Ingenuity Systems, Silicon Valley, CA) was used
as previously described (17–20), (23). Pathway analysis has been
demonstrated to highlight causative genes and mechanisms of dis-
ease in carefully conceived experimental paradigms (24). IPA dynam-
ically generates networks of gene, protein, small molecule, drug, and
TABLE II
Antibody information
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disease associations on the basis of “hand-curated” data held in a
proprietary database. More than 90% of the information in this data-
base is “expert-curated” and is drawn from the full text of peer-
reviewed journals. Less than 10% of interactions have been identified
by techniques such as natural language processing. In the current
analysis, candidate interactions were limited to experimentally ob-
served interactions only but could be drawn from any source in the
IPA database. Networks generated by IPA were limited in this study to
ten networks comprising a maximum of 35 members per network. To
enhance the explorative interpretation of data, networks are ranked
according to a score calculated via a right-tailed Fisher’s exact test.
This test outputs a value that takes into account the original input
gene or proteins of interest and the size of the network generated. The
value enables the application to approximate how relevant the net-
work is to the current analysis. It should be noted that this score does
not indicate the biological relevance or quality of the network, which
remains the prerogative of the analyst. Further information on the
computational methods implemented in IPA can be obtained from
Ingenuity Systems (http://www.ingenuity.com/).
Statistical Analysis—Unless otherwise stated, data were collected
into Microsoft Excel spread sheets and analyzed using GraphPad
Prism software. For all analyses p 	 .05 was considered to be
significant. Individual statistical tests used are detailed in the results
section or figure legends as appropriate.
RESULTS
Differential Proteomic Analysis of the Cranial (Superior) Cer-
vical Ganglia (CCG) Reveals Widespread Proteome Disruption
in Equine Grass Sickness (EGS)—A Multiple System Neurop-
athy—EGS-affected horse samples were collected immedi-
ately after horses were euthanized on humane grounds due to
disease severity (median 2, range 1–6 days after the first
onset of abnormal clinical signs) (Fig. 1 and Table I). At this
stage of disease, histological examination commonly indi-
cates that the majority of CCG neurons are undergoing acute
neurodegeneration, and although neuronal density remains
unaltered (Figs. 1C and 1D and Supplemental Fig. 1), there is
likely to be a spectrum of stages of neurodegeneration pres-
ent, ranging from neurons in the late stages of acute neuro-
degeneration to those with relatively normal morphology (see
Fig. 1E and (14)).
Using an iTRAQ quantitative proteomic approach, total pro-
tein extracts from six EGS patient CCG and six control sam-
ples were examined (See Fig. 2 and Materials and Methods
section for details). 219,347 individual peptide sequences
were submitted to Mascot (2.2) for identification using two
separate databases (equidae and mammalia) due to the com-
parative lack of annotation within the equidae database. Mas-
cot analysis returned identification of 2,311 proteins (Fig. 3,
left data column and Supplementary Data File 1). Data were
filtered to yield a final list of proteins altered in EGS CCG by
only including those proteins identified by at least two unique
peptides. Moreover, consistent with previously published
methodologies to increase stringency in reporting, a minimum
cutoff of 20% change versus controls was used as previously
described (17–20, 23, 25, 26) (Fig. 3). This process resulted in
the identification of 320 proteins that were considered to have
increased levels in EGS ganglia and 186 with decreased ex-
pression (Fig. 3; Supplemental Tables 1 and 2). We therefore
consider this refined list of 506 proteins to be representative
of the molecular alterations induced by EGS neurodegenera-
tive processes in CCGs. Due to the limited molecular inves-
tigations into EGS to date, the vast majority of proteins iden-
tified here with altered expression had not been previously
associated with this disease.
To determine the veracity of the proteomic data, candidates
were first selected for validation based on factors such as
magnitude of change in the proteomic data set and potential
relevance to neurodegenerative disease from the published
literature. Candidates of immediate interest included BPI fold
containing protein/parotid secretory protein (PSP—3.96 EGS/
control ratio), amyloid beta precursor protein (APP—3.66
EGS/control ratio), and various components of the ubiquitin
proteasome system (UPS; Fig. 3). PSP was of interest as a
FIG. 3. Proteomic analysis identified 506 alterations in EGS
CCG. Scatter plot providing a graphical representation of the filtering
process undertaken on the raw proteomics data in order to generate
a final list of proteins altered in EGS compared with control CCG (26).
Proteomic data were obtained by analyzing six control and six EGS
horse CCG, and data are presented as expression ratios (EGS/control
CCG) with each datum point representing an individual protein. The
red bars indicate the 20% cutoff threshold for being up- or down-
regulated in EGS ganglia compared with controls. Prefiltered (LHS)
and postfiltered (RHS) data. Of the 2,311 proteins that were identified
through iTRAQ analysis only 506 of those were considered differen-
tially expressed following filtering. See Materials and Methods for
further information on data filtering.
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potential serum biomarker to aid diagnosis of EGS. APP was
selected for validation due its repeated association with var-
ious human neurodegenerative conditions, including but not
limited to Alzheimer’s disease (27), prion diseases (28),
tauopathies (29), murine neurodegenerative disease models,
and as part of an acute phase response to neuronal injury (30).
Altered expression of multiple components of the UPS was
identified for follow up as specific ubiquitin cofactors such as
ubiquitin carboxy-terminal hydrolase and PGP permeability
glycoprotein (UCHL1/PGP) 9.5 have previously been reported
in association with altered nasal mucosal and enteric inner-
vation in EGS (31, 32) and various perturbations of the UPS
have been implicated in multiple human neurodegenerative
conditions, including but not limited to spinal muscular atro-
phy, Huntington’s, Alzheimer’s, and Parkinson’s diseases (20,
33–36).
Having selected candidates for validation, we began veri-
fying the accuracy of the proteomic data by performing QFWB
as previously described (17–21, 23). To confirm equivalent
protein loading we carried out a total protein analysis with an
Instant Blue stain (Fig. 4B; (21)). Total protein was used rather
than conventional loading controls as these are frequently
altered in tissue from neurodegenerative conditions and the
EGS CCG proteomic data suggested that beta-actin (fre-
quently used as a loading control) may be down regulated by
22% (0.78 EGC/control ratio; Supplemental Table 2). We can
confirm (as demonstrated by QFWB) that both PSP and APP
are indeed changed in the direction and to the approximate
magnitude indicated by the proteomic data (3.08  0.83,
3.82  0.8—ratio EGS/control mean  S.E., respectively;
Figs. 4B-4D). Interestingly, it was possible to identify differ-
ential expression alterations in both mono- and multimeric
ubiquitin, confirming that not only are specific UPS compo-
nents altered but also that ubiquitin oligomerization profiles
are different in EGS CCG. Here, we see an increase in “free”
monomeric ubiquitin and a corresponding decrease in multi-
meric (-trimeric) ubiquitin (1.23  0.06, 0.58  0.09—ratio
EGS/control mean S.E., respectively; Figs. 4A and 4E). This
QFWB data therefore indicate that the proteomic analysis is
likely to be an accurate reflection of the molecular alterations
occurring in EGS neural tissue.
Cellular Expression and Distribution Profiles of PSP, APP,
and Ubiquitin Are Altered in EGS CCG—Given the status of
proteins associated with misfolded protein responses in the
pathogenesis of a broad range of neurodegenerative condi-
tions in humans, we next wanted to extend the validation of
our proteomic analysis to examine these candidates at the
cellular level. While quantification by QFWB on whole tissue
protein homogenate is a useful technique for determining
relative protein expression levels, in this case, it only provides
an indication of protein abundance irrespective of conforma-
tion or subcellular localization. Given the heterogenous cellu-
FIG. 4. Candidate validation of proteomic data by quantitative fluorescent Western blotting. (A) Representative examples of bands used
for quantification of total protein load, PSP, APP, and ubiquitin. (B–E) Graphical representation (bar charts; mean  S.E.) of relative expression
for total protein load and each candidate are given. Direction and magnitude of changes are consistent with iTRAQ data. All alterations were
statistically significant (n  4 horses per condition; unpaired two-tailed t test where *P0.05; **p 	 .01; ***p 	 .001).
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lar nature of the CCG (see Supplementary Discussion file) and
the complex cellular functions of the proteins selected for
validation by QFWB, we next sought to examine their expres-
sion profiles at the cellular level. Here, we carried out DAB-
based IHC with whole plane analysis of reconstructed CCG.
Each staining run and subsequent analysis comprises the
examination of whole reconstructed sections (approximately
80 images at 10X magnification each—see Materials and
Methods) from three EGS (two acute and one subacute) and
three control ganglia (Fig. 5A). Having identified PSP by
proteomic analysis and confirmed its alteration by QFWB, it
appears from IHC that the increased expression is predom-
inantly within cell bodies of EGS CCG (Figs. 3, 4A, 4C, and
5B). APP is a highly conserved protein (37), integral to
cellular membranes and enriched in neurons (38). When we
examined EGS sections for APP expression, there were
obvious increases in cellular APP (Fig. 5C). Interestingly, the
APP immunostaining is not purely membrane bound but
appears as strong diffuse cytoplasmic staining with “rings”
of APP denoting the membrane boundary of the cell. The
staining intensity and subcellular distribution of APP sug-
gests that the increase in APP expression reflects either
increased protein synthesis and/or failure of APP transport
from the perikaryon to the nerve terminus, perhaps corre-
lating with previously reported defects in the Golgi appara-
tus and axonal transport (13).
Ubiquitin is a protein with complex roles within neurons.
Upon further examination by QFWB (Figs. 4A and 4E) an
FIG. 5. Cellular expression of candidates further validates proteomic data confirming disruption of APP and the UPS. (A) Example
whole CCG section reconstruction from one control and one (acute) EGS ganglia. Each reconstruction comprises80 images captured at 10X
magnification. See methods for further information. (B–D) Representative images of DAB based immunohistochemistry to examine the cellular
expression profiles of candidate proteins, including PSP, APP, and ubiquitin. (E) Quantification of ubiquitin expression demonstrates an
increased trend in cells with diffuse cytoplasmic staining (88.8% 47.4) and a decrease in dense nuclear staining of 62.3  7.2% in EGS CCG
compared with control CCG. (mean S.E.; n 3 ganglia per condition (EGS 2 acute and 1 subacute; 400–600 cells per ganglia) scale bar
100 m (B–D).
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increase in “free” mono ubiquitin (see Supplementary Tables;
Fig. 3; (39)) and a resulting reduction in higher-order oligomers
was seen. This is consistent with increased expression of
deubiquitinating proteins such as members of the UCHL fam-
ily (Supplemental Table 1). In neurons, such alterations result
in an increase in diffuse ubiquitin staining (cytoplasmic) and a
reduction in dense nuclear staining (higher-order oligomers)
such as shown in EGS ubiquitin immunostained CCG sections
relative to controls (Fig. 5D). Similar accumulations have pre-
viously been reported in TG22/UCHL1 overexpressing mice
(39). Quantitative assessment of these sections demonstrates
an increased number of cells with strong diffuse perikaryon
staining (88.8% 47.4; mean  S.E. n  3 ganglia per con-
dition; 400–600 cells per ganglia) and a decrease in the
appearance of dense nuclear accumulations 62.3  7.2%
(mean  S.E. n  3 ganglia per condition; 400–600 cells per
ganglia) in EGS horses compared with controls. This informa-
tion therefore serves to further verify the robust nature of the
proteomic characterization of the molecular alterations taking
place in EGS ganglia. Moreover, these data represent the first
demonstration that the neurodegenerative processes in EGS
share some molecular characteristics described in other neu-
rodegenerative conditions, including humans and their murine
models such as the accumulation and/or redistribution of
proteins such as APP and ubiquitin.
In silico Analysis Highlights Evolutionarily Conserved Mo-
lecular Neurodegenerative Alterations and Higher-Order
Candidate Clustering in EGS—Having confirmed the verac-
ity of the proteomic data, we attempted to obtain further
insights into potential molecular pathways and processes
that may be modified by explorative in silico analysis using
IPA software (see Materials and Methods). This application
was used to identify direct and indirect molecular interac-
tions, pathway associations, and functional assignments
involving the filtered candidate list (Fig. 3, RHS; Supplemen-
tal Tables 1and 2).
Of the 506 proteins identified as altered in our proteomic
comparison, those differentially expressed proteins that were
adequately annotated to be eligible for in silico analysis, using
the IPA database (Table III), clustered predominantly into the
following higher-order biofunctions: (1) diseases and disor-
ders, including neurological disease (32%), skeletal and mus-
cular disorders (24%), and (2) molecular and cellular func-
tions, including cellular assembly and organization (41%),
cell-to-cell signaling and interaction (18%, including epineph-
rine, dopamine, and adrenergic signaling and receptor func-
tion), and small molecule biochemistry (25%). Interestingly,
closer examination of the diseases and disorders biofunction
suggests that up to 20% of the candidates have previously
been reported in the published literature as being associated
with specific neurodegenerative disease, including but not
limited to Huntington’s, Parkinson’s, and motor neuron dis-
eases (Table IV). To further explore the implication that com-
mon molecular correlates of neurodegenerative processes
have been observed, we carried out a small-scale comparison
of candidates identified here as being differentially expressed
in EGS affected compared with control tissue, with existing
published data from a mouse model of a neurodegenerative
condition (SMA; See (18) for original published dataset) and a
model of neuroprotection (Wlds; see (17) for original published
dataset; Fig. 6). This comparison confirms that several candi-
dates identified in EGS are also altered in both SMA-mediated
neurodegenerative processes (12% of SMA candidates) and
Wlds-mediated neuroprotective processes (8% of Wlds can-
didates). While this overlap in datasets is limited, it does yield
interesting insights, i.e. those that may be contributing to the
degenerative responses (conserved in SMA and EGS), those
that may be generic responses to a neurodegenerative insult
(conserved in Wlds and EGS in direction), and those that may
be regulatory in nature (opposite in Wlds and EGS) (Fig. 6). For
example, members of the catenin family have been implicated
as drugable regulators of degenerative processes in disease
(Supplemental Fig. 2; (20)) and members of the cathepsin
family are known to instigate degenerative processes in lys-
osomal storage disorders (40). This information coupled with
an examination of cellular processes highlighting an associa-
tion with neuronal morphology and function (Table IV) sug-
gests that many of the molecular processes occurring in EGS
ganglia may be consistent with fundamental neurodegenera-
tive processes, likely conserved across different conditions
and species. These data, therefore, highlight the value of
applying differential proteomics techniques to the compara-
tive investigation of neurodegeneration in spontaneous hu-
man and animal diseases.
IPA Analysis of Multiprocess Interactions Highlights an
APP-Centric Network—Coupled with the demonstration that
the ubiquitin system and APP abundance and distribution are
perturbed in EGS (Figs. 3, 4A, 4D, and 5C), IPA-based path-
way analysis highlighted a network that appears likely to
represent a molecular system whose perturbation may be
actively contributing to EGS-induced neurodegenerative pro-
cesses (Fig. 7). This network comprises functions associated
with cell-to-cell signaling and interaction, nervous system de-
velopment and function, and small molecule biochemistry
(n  38% of candidates from Table III; Fig. 7). In this network,
APP is a central hub with both direct and indirect interactions
encompassing a high proportion of the protein components
(23/35 molecules, or 65%) with more than half of these orig-
inating from APP (14/23 molecules, or 61%). In combination
with the molecular and cellular data provided in this study
demonstrating a perturbation of the abundance and cellular
localization of APP (Figs. 3, 4, and 5) and its existing high
profile associations with a range of human neurodegenerative
conditions (36–38), this, therefore, identifies for the first time
APP as an attractive candidate as a potential regulator for the
processes observed in EGS.
In Silico Analysis Predicts Upstream Regulators of EGS
Identified Alterations—IPA software now provides the tools to
Proteomic Characterization of an Equine Multiple System Neuropathy
3080 Molecular & Cellular Proteomics 14.11
TABLE III
Proteins compatible with Ingenuity Pathway Analysis Database
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predict potential upstream regulators of the functions that
may be perturbed in the system of interest (24). These poten-
tial upstream regulators (transcriptional or translational) are
correlative with the observed expression differentials in a
specific subset of submitted data and may aid in the identifi-
cation of cascade initiators. Table V lists the top five proposed
upstream regulators ranked by p value. All of the five potential
regulators highlighted by this analysis are interesting pre-
dictions for a number of reasons. They have all been impli-
cated in human neurodegenerative conditions in which pro-
tein aggregation/misfolding is a pathophysiological hallmark
(41–45). Tau is an interesting potential candidate because
of its reported association with a range of human neurode-
generative conditions. Additionally, PP2A, which accounts
for 70% of Tau phosphatase activity, also occupies a
potential regulatory hub in Fig. 7. Other factors that can
regulate neurodegeneration in their own right and degrade
Tau are also decreased in EGS (i.e. cathepsin D, Table III).
TABLE IV
Ingenuity Pathway Analysis of Higher Order Functional Clustering
FIG. 6. Venny-based comparison of EGS protein alterations highlights molecular overlaps with published datasets from systems with
altered neuronal stability. Schematic representation of the overlaps between EGS proteomic data and that from murine models of
neuroprotection (Wlds) and the human neurodegenerative disease spinal muscular atrophy (SMA). SMA is an inherited childhood neurode-
generative condition and data used in this alignment have previously been published in (17). Wlds represents a spontaneous mutation resulting
in a neuroprotective phenotype. The dataset used for comparison here is taken at 2 days following a corticostriatal lesion in which Wlds tissues
demonstrate no signs of neurodegenerative processes. The original data can be found in (18). 12% of SMA candidates and 8% of Wlds
candidates are also found in the EGS analysis indicating overlap with other neurodegenerative processes at the molecular level (18% of viable
EGS candidates). Interestingly, the data highlight candidates that may contribute to the degenerative responses (conserved in SMA and EGS),
those that may be generic responses to a neurodegenerative insult (conserved in Wlds and EGS in direction), and those that may be regulatory
in nature (opposite in Wlds and EGS).
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Here, we can confirm by QFWB that Tau is more abundant
in EGS but only in the acute form (Supplemental Fig. 2). It is
therefore likely that Tau alterations are consequential rather
than causative. Prion protein has previously been consid-
ered as a potential initiator of the disease process in EGS,
but this has never been proven, and prion protein was not
present in our dataset. However, QFWB of CCG protein
isolates from EGS and control horses suggests that there is
FIG. 7. Pathway analysis highlights APP is a central hub interacting with nearly 40% of candidate molecules in EGS. This interaction
network (comprising aspects of cell–cell signaling and interaction, nervous system development, and small molecule biochemistry) involves
38% of IPA viable candidates with modified expression in EGS. Proteins within this network identified as being modified in EGS CCG are
indicated using adjacent circles (red, up-regulated in EGS; green, down-regulated in EGS; clear, absent from our dataset but integral to the
network). Solid connecting lines indicate a direct interaction, and dashed connecting lines indicate an indirect interaction. Blue connecting lines
represent the highlighted interactions of APP. All suggested indirect interactions were confirmed manually using Ingenuity Pathways Analysis
software to identify published evidence indicating an interaction between the two proteins.
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no disease-associated prion protein (PrPres) present (Sup-
plemental Fig. 3). Of the proposed upstream regulators, only
APP appeared in the functional clustering/network analysis
of the proteomic data. This further supports the data pre-
sented above and strengthens the suggestion that APP may
be a key regulatory protein in EGS-related degenerative
processes.
DISCUSSION
Patient Tissue Profiling Yields Insights into Molecular Pro-
cesses that Must Be Considered in Accordance with Disease
Staging—While studies of neurodegenerative diseases utiliz-
ing post-mortem patient tissues remain constrained by sam-
ple availability, the data presented here represent a combined
molecular snapshot of late-stage disease processes from six
horses with a spontaneous multiple system neuropathy (EGS)
in comparison to six unaffected controls. Importantly, signif-
icant perturbations of the cellular proteome are evident even
from analysis of a heterogeneous population of EGS animals
(Table I), suggesting that many of the alterations identified are
likely to be fundamental in the progression of this disease.
At the stage of disease when CCG samples were collected,
histological examination indicates that CCG neurons are un-
dergoing a spectrum of stages of neurodegeneration and that
the majority are undergoing acute neurodegeneration. Con-
sequently, the proteome of EGS CCG extracts will likely re-
flect the overall range of proteins originating from individual
neurons at various stages of degeneration. Therefore, pro-
teins representative of nonspecific neuronal death responses,
as well as representatives of the processes initiating and
regulating the neurodegenerative progression of EGS, will
have been identified (see Fig. 5). The altered expression levels
of distinct neural proteins documented in the current study
may prove helpful not only for deepening our understanding
of the pathophysiology of EGS but also for the future estab-
lishment of a comprehensive molecular signature of the
disease.
To address the, albeit unlikely, possibility that the extracts
from EGS CCG contained a protein neurotoxin derived from a
causal bacterium or fungus, iTRAQ data were also run
through NCBIs all species and bacterial databases. While
Mascot analysis returned identification of 2,301 in the all
species database (Supplementary Data File 1), it only identi-
fied 37 proteins in the bacterial database (Supplementary
Data File 2). However, none of these were known toxins or
were considered to be of relevance to the aetiopathogenesis
of EGS. It is important to note that this does not preclude EGS
being caused by a bacterial or fungal neurotoxic protein. It
remains possible that the coverage of the proteome may be
insufficient to facilitate toxin identification, a toxin may be
present at concentrations below detection limits, or a toxin
may not persist within the CCG of EGS horses.
Equine Proteomic Profiling Reveals Similarities to Other
Neurodegenerative Conditions—Specific alterations in the
EGS CCG proteome included multiple members of the ubiq-
uitin proteasome system (UPS) (Fig. 3). Here, we identified
many ubiquitin expression alterations, including a range of
UCH family members, Ubas, and ubiquinone (Fig. 3, Supple-
mental Tables 1 and 2). Specific ubiquitin cofactors such as
UCHL1/PGP 9.5 have previously been reported in association
with altered innervation in nasal mucosal (31) and autonomic
ganglia (32) in EGS. Ubiquitination is a key regulator of cellular
homeostasis through its involvement in the management of
protein misfolding, sequestration, degradation, and process-
ing, including the processing of APP ((46); ubiquinone—
Supplemental Table 2). Perturbations of the UPS have been
implicated in various human neurodegenerative conditions,
including; Alzheimer’s, Huntington’s, Parkinson’s, and motor
neuron diseases (20, 33–36). Moreover, through pathway
analysis of the data generated in this study, we highlighted
similarities and potentially conserved molecular processes
between these prominent human neurodegenerative condi-
tions and this equine multiple system neuropathy (Table IV,
Fig. 5). Further discussion of specific candidates of specific
interest to the neurodegenerative and equine clinical commu-
nities, which would detract from the focus of the manuscript,
can be found in the accompanying supplementary discussion
text (Supplementary Discussion File 1).
Analysis of Higher-Order Functional Clustering Yielded Sev-
eral, Previously Unreported, Insights into the Processes Un-
derpinning EGS Pathogenesis—For example, one of the cel-
lular processes identified as being significantly altered in
EGS was synaptic transmission (Table IV). The differentially
expressed proteins associated with synaptic transmission,
APOE, APP, SNAP25, and STXBP1, are also involved in
regulating presynaptic terminal stability and synaptic vesi-
cle fusion. Moreover, these proteins have also been re-
ported in association with epilepsy, ataxia, and Parkinson’s
TABLE V
Ingenuity Pathway Analysis - Top Five Predicted Upstream Regulators
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disease (47–51). It is therefore highly likely that dysregula-
tion of these proteins contributes to neurodegeneration in
EGS.
Additionally, it appears that the proteins identified by clus-
tering analysis and proteins whose expression is consistent in
other neurodegenerative diseases (i.e. citrate synthase—CS
in SMA) or correlate with vulnerability status (i.e. cathepsin
D—CTSD in Wlds; see Fig. 5) all share a common upstream
regulator—APP. Upstream regulator analysis of the altera-
tions identified in EGS highlighted a broad range of candi-
dates associated with numerous human neurodegenerative
diseases, many of which are characterized by protein misfold-
ing and/or aberrant accumulation (Table V, Supplemental
Figs. 2 and 3 (52–54)). In combination with confirmation of
altered abundance (proteomics and QFWB), histological dem-
onstration of mislocalization, and its identification as a central
hub interacting with 65% of the members of a functional
network (Fig. 7), APP therefore appears to be the most prom-
ising candidate upstream regulator of the alterations detailed
in the current study. As such, APP is likely to be a regulator of
EGS pathogenesis.
Summary—Reliable markers with potential modulatory abil-
ity are urgently required to improve both diagnostic and ther-
apeutic efficacy, and these remain the key challenges for all
neurodegenerative disease research. This is the first applica-
tion of modern proteomic tools and in silico analytical tech-
niques to equine neuronal tissues and/or to an inherent neu-
rodegenerative disease of large animals (not a model of
human disease). As such, it has facilitated the identification of
more than 500 protein alterations in equine grass sickness
cranial (superior) cervical ganglion, most of which had not
been previously linked with EGS. This is also the first demon-
stration of correlation and conservation for neurodegenerative
molecular cascades spanning from an apparently unrelated
large animal neuropathy, small animal models of altered neu-
ronal vulnerability, and a broad range of human neurological
conditions. Finally, this study highlights the feasibility and
benefits of applying differential proteomics techniques to the
investigation of the neurodegenerative processes in diseases
of large animals.
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